Press Release


Zhaoke Ophthalmology Announces 2022 Interim Results
Aug 24, 2022 20:37 JST
Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the six months ended 30 June 2022 ("Reporting Period").
More info..

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002
Aug 03, 2022 10:16 JST
Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or "the Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development
More info..

Two Products of Zhaoke Ophthalmology (6622.HK) Passes On-Site Inspection for Drug Registration by National Medical Products Administration and GMP Compliance Inspection by Guangdong Medical Products Administration
May 24, 2021 16:56 JST
Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs
More info..

Latest Release


More Latest Release >>